Rondecabtagene Autoleucel
Diffuse Large B Cell Lymphoma Refractory
Lyell Immunopharma, Inc.Cell therapyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
107 Active assets in the Diffuse Large B Cell Lymphoma Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selinexor Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 2/3 | BB |
Axicabtagene Ciloleucel Zhujiang Hospital | Phase 3 | BB |
Cyclophosphamide Nathan Denlinger | Phase 3 | BB |
ETOPOSIDE University of California, Davis | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Rondecabtagene Autoleucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →